Skip to main content

AI Bias Analysis

4 models · Takes ~15 seconds

Stat News

STAT+: Publicly, Kennedy embraces a more moderate MAHA

STAT+: Publicly, Kennedy embraces a more moderate MAHA
ShareXFacebook

Kennedy continues to make waves across health care, but he's pulled back on a number of core MAHA issues.

S

Source

Stat News

Read full article at Stat News

Opens original article in a new tab

Advertisement

Related Health Stories

First Clinical Trial in MOGAD Meets Primary Endpoint
MedPage Today

First Clinical Trial in MOGAD Meets Primary Endpoint

(MedPage Today) -- The interleukin-6 (IL-6) inhibitor satralizumab (Enspryng) met its primary endpoint in the phase III METEOROID trial of myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). Satralizumab reduced the risk of...

Read more →
Advertisement